4TH ANNUAL ASH 2018 UPDATES:
PRACTICE CHANGING ABSTRACTS
For More Info: ChicagoPostAsh.com

February 15, 2019
University of Chicago
The Gleacher Center
450 Cityfront Plaza Dr,
Chicago, IL 60611

Keynote:
Steven Schuster, MD
University of Pennsylvania
CAR T-Cell Therapy for NHL
COURSE DESCRIPTION

Patients in medically underserved communities have limited access to subspecialty care. Community-based oncologists are well positioned to provide initial care for these patients, but often do not have the knowledge and confidence to manage difficult cases.

According to the 2015 Community Health Needs Assessment, between 2006 and 2008, the City of Chicago experienced an annual average adjusted cancer mortality rate of 194.2 deaths per 100,000 individuals. Cancer mortality has decreased over the past decade in Cook County; the same trend is apparent both statewide and nationwide. Although both trends are decreasing, Cook County cancer related mortality is greater than the national average deaths per 100,000 individuals. Also, city of Chicago cancer mortality rates are higher than regional, state, and national cancer death rates. University experts in hematological cancers agree that we need to join our regional cancer community to lower our county and state mortality rate. Also, many local health professionals do not have the time or resources available to attend the annual updates from ASH 2017 conference where the latest scientific and clinical research in blood cancers is discussed, so they need a venue in which they can learn about these important updates.

TARGET AUDIENCE

This activity has been designed for physicians and other healthcare professionals interested in the treatment of hematologic cancers.

LEARNING OBJECTIVES

- Discuss how comprehension of biology of leukemias has influenced treatment approaches;
- Describe next generation improvements in CAR T-Cell therapies that can improve patient outcomes;
- Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
- List current best practice in first and second line therapies for lymphoid malignancies;
- Name new technologies for the treatment of hemophilia;
- Analyze how new scientific insights are informing diagnosis and treatment of myelodysplastic/myeloproliferative neoplasms.
**AGENDA: FEBRUARY 15, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30—1:00 pm</td>
<td>Registration and Exhibits</td>
<td></td>
</tr>
<tr>
<td>1:00—1:30 pm</td>
<td>Scientific Progress in Leukemia</td>
<td>Richard Larson, MD</td>
</tr>
<tr>
<td>1:30—2:00 pm</td>
<td>Myelodysplastic Syndrome and Myeloproliferative Neoplasms</td>
<td>Toyosi Odenike, MD</td>
</tr>
<tr>
<td>2:00—2:30 pm</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>2:30—3:00 pm</td>
<td>Practice Changing and Promising New Treatments in Multiple Myeloma</td>
<td>Andrzej Jakubowiak, MD, PhD</td>
</tr>
<tr>
<td>3:00—3:30 pm</td>
<td>Advances in Cellular Therapy</td>
<td>Peter Riedell, MD</td>
</tr>
<tr>
<td>3:30—4:00 pm</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>4:00—4:30 pm</td>
<td>Evolving Standards of Care in Lymphoma</td>
<td>Sonali Smith, MD</td>
</tr>
<tr>
<td>4:30—5:00 pm</td>
<td>Clinical Updates in Clotting Disorders</td>
<td>Kenneth Cohen, MD</td>
</tr>
<tr>
<td>5:00—5:45 pm</td>
<td>CAR T-Cell Therapy in Non-Hodgkin Lymphoma</td>
<td>Steven Schuster, MD</td>
</tr>
<tr>
<td>5:45—6:00 pm</td>
<td>Close</td>
<td></td>
</tr>
</tbody>
</table>

**Faculty Disclosure:** As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

**Educational Grants/Commercial Support:** A complete listing of commercial support received will be provided in the conference materials.
ANNUAL UPDATES FROM ASH 2018: PRACTICE CHANGING ABSTRACTS

Chicago, Illinois | February 15, 2019

Course Director: Michael Bishop, MD
Director of the Hematopoietic Cellular Therapy Program
University of Chicago Medicine

ACCREDITATION STATEMENT
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

ADDITIONAL INFORMATION
For information regarding course, contact Meeting Achievements at 219.465.1115 or email polly@meetingachievements.com